Hybio Pharmaceutical Co., Ltd.
300199
Pozycja w akcjach
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Cena akcji
$3.69
Kapitalizacja rynkowa
$3.11B
Zmiana (1 dzień)
-7.75%
Zmiana (1 rok)
21.56%
Kraj
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Kategoria
Healthcare
Zyski dla Hybio Pharmaceutical Co., Ltd. (300199)
Zyski w Jun 2026 TTM: $23.66M
Według najnowszych raportów finansowych Hybio Pharmaceutical Co., Ltd., obecny zysk firmy wynosi $23.66M. W roku 2024 firma osiągnęła zysk w wysokości $-22.25M, wzrost w porównaniu do zysku z roku 2023, który wynosił $-72.20M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Hybio Pharmaceutical Co., Ltd. od 2007 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $23.66M | 157.76% |
| 2025 | $9.18M | -141.26% |
| 2024 | $-22.25M | -69.18% |
| 2023 | $-72.20M | 33.59% |
| 2022 | $-54.05M | -1,119.96% |
| 2021 | $5.30M | -105.88% |
| 2020 | $-90.05M | -29.65% |
| 2019 | $-128.00M | 163.83% |
| 2018 | $-48.52M | -190.05% |
| 2017 | $53.88M | 20.99% |
| 2016 | $44.53M | -14.53% |
| 2015 | $52.11M | 73.20% |
| 2014 | $30.08M | 23.42% |
| 2013 | $24.38M | 44.61% |
| 2012 | $16.86M | 13.35% |
| 2011 | $14.87M | 79.07% |
| 2010 | $8.30M | 48.60% |
| 2009 | $5.59M | 70.78% |
| 2008 | $3.27M | 57.76% |
| 2007 | $2.07M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $3.62B | 15,188.96% |
DE
|
|
| $3.40B | 14,289.34% |
DE
|
|
| $1.72B | 7,183.94% |
JP
|
|
| $930.30M | 3,831.42% |
CH
|
|
| $1.76B | 7,356.94% |
IN
|
